09.05.25 -- The Hidden Risk In Cell & Gene Therapy Commercialization

Experts highlight critical concerns regarding insufficient cold chain infrastructure for cell and gene therapies, emphasizing an urgent need for robust, scalable solutions to meet future demand.

While barrier films in bags can be useful for cold chain applications, they do not fully protect against gas ingress and ignore other sources of permeability.

Discover a new AI Copilot that revolutionizes clinical data analysis and offers seamless deployment with intuitive question-answering, chart generation, and content integration.

Audit trails are not only a regulatory necessity but a strategic tool to ensure data reliability and accelerate high-quality clinical research outcomes.

Clinical trials frequently encounter delays, and rescue studies have become vital to address this challenge, especially in complex therapeutic areas.

Learn how community- and patient-centric site networks that have DCT capabilities are able to work with a broad-range of site types.

Frank David, Founder and Managing Director of Pharmagellan, discusses how mission, vision, and data analysis fit into today's biotech goals.

The initial IRB submission process can involve common challenges. To help you overcome these obstacles, discover seven fundamentals you should know about a successful initial IRB submission.

Learn how to develop and utilize a successful DCT framework, enabling your study to enhance patient access, improve data quality, and streamline study operations.